BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Report Library

All Reports
Datamonitor Healthcare Oncology Disease Analysis: Multiple Myeloma

May 07, 2021

Multiple myeloma (MM) is a hematological malignancy characterized by the infiltration of malignant, antibody-producing plasma cells in the bone marrow. The disease represents approximately 1% of all cancers, and 10% of hematological cancers. The hallmarks of MM are high levels of monoclonal (M-) protein, high levels of clonal plasma cells in the bone marrow, and organ damage. Plasma cells normally produce antibodies in response to infection or allergens, but in MM a plasma cell clone starts to proliferate and produce excessive amounts of one type of abnormal antibody, referred to as M-protein or paraprotein. In addition to high levels of M-protein, most patients with active MM have some form of organ damage caused by the proliferation of plasma cells and the high levels of protein in the blood and urine. Typical signs of organ damage include hypercalcemia, renal insufficiency, anemia, and bone lesions.

This Datamonitor Healthcare report contains a Disease Analysis module.

Indications Covered: Multiple Myeloma (MM)
Back to the top Back to the top